Member Info for eggonaroll

Small rise on openning as mms dont understand how important this update was

What we need now is another deal to underpin value to market or even 10 deals

The end game here is many billions mkcap

It couldnt have been better

All three subjects in the first cohort of the Phase 2a element of the study have demonstrated a sustained and further improvement in vision compared with their pre-treatment baseline.

So their eyes have got better over longer period and are getting better as time passes!

They are presenting 10pm uk time so just as likely Monday.

Well thats next week@ gla roll.on 7am

You have a very good chance if they nail this company is worth billions

Should be up 10% if game wasnt being fixed... try buying volume right now

Can you imange the excitment with stakeholders the blind and nhs if those results come in. They will have cracked it

It really is a load of boll.... been the game since tuesday.... 7am tomorrow should see some fireworks

To be fair thats what i said. Expecting 7am tomorrow or if they want to be dramantic at conference monday 7am

saying that be mad if not buying into the bell as im 90% sure it has to come at 7am

proper news comes at 7am

All those buys where based on last results as they know they are hitting gold. New results only know now so its all in order. Likely we know tomorrow

I know its old but a great summary and highlights what we are getting friday... the purpose of this board is spell out plus and negatives to potential new investors. When the rns hits they will come look here. That summary is a great starter. Then they need to understand potential value of product timelines and what happens with success which is a big company comes in and boom they buy the product and likely the company and from these levels we are rich

Friday after hours they must know them by morning? Rns can drop any time

Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its \'hRPC\' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.
The AIM-traded company had reported in February that all three of the first cohort of subjects in the study had reported a \"rapid and significant\" improvement in vision, on average equivalent to reading an additional three lines of five letters on the ETDRS eye chart - the standardised eye chart used in clinical trials to measure visual acuity.

Last month, it announced that dosing of the second cohort of three phase 2 subjects had begun.

That next dose cohort comprised patients who had a greater baseline level of visual acuity than those treated in the study thus far.

Further read-outs from the patients treated in the study would be presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada on 26 April.

ReNeuron said it would make a further announcement later in April, when those further read-outs from the study were known.

The company said its RP clinical programme benefited from \'Orphan Drug Designation\' in both Europe and the US, as well as \'Fast Track\' designation from the FDA.

\"We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing phase 1 and 2 study with our hRPC cell therapy candidate for retinitis pigmentosa,\" said chief executive officer Olav Hellebø.

\"We look forward to providing a further update on progress with the study at the time of the Innovation Summit in Vancouver later this month.\"

John Berriman, Chairman, bought 80,000 shares in the company on the 11th April 2019 at a price of 225.00p. The Director now holds 90,434 shares.
Simon Cartmell, Non Executive Director, bought 7,758 shares in the company on the 11th April 2019 at a price of 225.55p. The Director now holds 15,633 shares.
Prof Sir Chris Evans, Non Executive Director, bought 4,500 shares in the company on the 11th April 2019 at a price of 221.50p. The Director now holds 244,605 shares.
Dr Mike Owen, Non Executive Director, bought 4,237 shares in the company on the 11th April 2019 at a price of 236.00p. The Director now holds 4,237 shares.
Prof Sir Chris Evans, Non Executive Director, bought 10,000 shares in the company on the 18th April 2019 at a price of 228.70p. The Director now holds 254,605 shares.